



## National Medicines Policy - Response to the Consultation Draft

Following the Review of the National Medicines Policy the Expert Advisory Committee collated feedback and created a draft National Medicines Policy seeking feedback via survey responses.

The consultation process did not provide opportunity to provide a joint response, however as Cancer Council have previously worked closely with the Clinical Oncology Society of Australia (COSA), the Medical Oncology Group of Australia (MOGA) and the Cancer Nurses Society of Australia (CNSA) on the National Medicines Policy, we collaborated again to review responses for each organisation and then submitted separately.

Our submission recommended the NMP must have:

- A clearly articulated timeline (e.g. 2022-2032) and a stipulated review cycle (e.g. 5 yearly)
- A time limited evaluation plan with clear public reporting of goals/targets and policy achievements
- Governance responsibility clearly identified as sitting with the Commonwealth
- A major focus on developing solutions which enable people with specific conditions (e.g., cancer) to access safe and effective registered products which can be considered for subsidy. Specifically, the repurposing of prescription medicines in oncology which is also likely applicable to other therapeutic areas.
- Funding for implementation.

Once considered by the review team a copy of the submission will be available on the review website <https://consultations.health.gov.au/technology-assessment-access-division/consultation-draft-national-medicines-policy/>